Cargando…

PB2434: DONOR CELL INDUCING IMMUNE-TOLERANCE IMPROVED ENGRAFTMENT IN TΑΒ+ CELL DEPLETED HSCT IN PATIENTS WITH THALASSEMIA MAJOR

Detalles Bibliográficos
Autores principales:	Liao, Jianyun, Pu, Chaoke, He, Lan, He, Yuelin, He, Jujian, Chen, Dan, Lyu, Bo, Zhang, Weiwei, Tang, Haoran, Liu, Xinrui, LI, Chunfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429308/ http://dx.doi.org/10.1097/01.HS9.0000976444.28718.a3

Ejemplares similares

P1322: EFFECTS OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSA) FOR PRIMARY GRAFT FAILURE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA MAJOR
por: Liao, Jianyun, et al.
Publicado: (2023)

PB2462: IMPACT OF ENGRAFTMENT SYNDROME ON THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC/HAPLOIDENTICAL PERIPHERAL BLOOD HSCT IN A SINGLE CENTER IN MEXICO.
por: Daniel Garza Escobar, Juan, et al.
Publicado: (2023)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB2186: INTENSITY OF THE CONDITIONING REGIMEN AND TIMING OF AUTOGRAFT ENGRAFTMENT IN PATIENTS WITH MULTIPLE MYELOMA
por: Kostroma, I., et al.
Publicado: (2022)

PB2539: GEOGRAPHICAL PREVALENCE OF THALASSEMIA GENE MUTATION IN THE PHILIPPINES
por: Velasco, Manuel Jr, et al.
Publicado: (2023)

NODAL in paged ACC-2434
por: Guillaume, C
Publicado: (1982)

PB2544: GAUCHER-LIKE CELLS IN THALASSEMIA INTERMEDIA: IS IT A CHALLENGE?
por: Komninaka, Veroniki, et al.
Publicado: (2023)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

PB2238: ΒETA-THALASSEMIA INTERMEDIA: INTERACTION OF ΑLPHA-GLOBIN GENE TRIPLICATION WITH ΒETA-THALASSEMIA HETEROZYGOUS IN SPAIN
por: Ropero, P., et al.
Publicado: (2022)

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
por: Merli, Pietro, et al.
Publicado: (2022)

PB2260: CIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A SINGLE CENTER EXPERIENCE
por: Cacace, F., et al.
Publicado: (2022)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

PB2543: CIRCULATING MICROVESICLES AS POTENTIAL CELLULAR BIOMARKERS FOR THROMBOTIC RISKS IN BETA THALASSEMIA
por: Chebbi, Mariem, et al.
Publicado: (2023)

PB2029: ACQUIRED ALPHA THALASSEMIA IN ASSOCIATION WITH MYELODYSPLASTIC SYNDROME- A CASE REPORT
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2533: FREQUENCY, PATTERN, AND CLINICAL CORRELATES OF RENAL IRON ACCUMULATION IN THALASSEMIA MAJOR
por: Meloni, Antonella, et al.
Publicado: (2023)

PB2538: FEASIBILITY AND SAFETY OF POWERPICC SOLO INSERTION THE SAPHENOUS VEIN IN CHILDREN WITH THALASSEMIA
por: Ren, Qin, et al.
Publicado: (2023)

PB2465: ALLOGENEIC HSCT OUTCOMES IN SIX PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS WITH A HISTORY OF OVARIAN CANCER TREATED WITH CHEMOTERAPY AND PARP INHIBITORS
por: Maria Edoardo Maraglino, Alessio, et al.
Publicado: (2023)

PB2339: PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
por: Udeze, C., et al.
Publicado: (2022)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
por: chen, M., et al.
Publicado: (2022)

PB2680: THE ACTOR-PARTNER INTERDEPENDENCE MEDIATION EFFECT OF INTIMATE RELATIONSHIP ON DYADIC COPING AND FEAR OF CANCER RECURRENCE IN PATIENTS AND THEIR SPOUSES WITH HEMATOLOGICAL MALIGNANCY AFTER HSCT
por: Zhang, Qiuhui, et al.
Publicado: (2023)

PB2439: EARLIER ENGRAFTMENT WITHOUT INCREASE OF GVHD IN HIGHER DOSE OF CD34+ CELLS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tan, Tran-Der, et al.
Publicado: (2023)

PB2234: HEALTH LITERACY LEVEL ASSOCIATED WITH THALASSEMIA AMONG TUNISIAN’S YOUTH AND PROSPECTS FOR PRIMARY PREVENTION
por: Maaoui, F., et al.
Publicado: (2022)

PB2228: PRECISION MEDICINE IN THALASSEMIA: 30-YEAR EXPERIENCE AT SINGLE INSTITUTE FROM SAUDI ARABIA
por: Al Jaouni, S.
Publicado: (2022)

PB2449: EFFECT OF MOBILIZATION METHODS ON CD34+ AND TOTAL NUCLEATED CELL COUNT AND THEIR RELATION WITH ENGRAFTMENT IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Beyler, Ozlem, et al.
Publicado: (2023)

Phenotypic and Functional Characterization of NK Cells in αβT-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia
por: Meazza, Raffaella, et al.
Publicado: (2020)

PB2233: SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE BURDEN IN PATIENTS ACROSS THE SPECTRUM OF THALASSEMIA
por: Musallam, K. M., et al.
Publicado: (2022)

PB2239: DOES SIZE MATTER? THREE NEW DELETIONS IN THE HBB GENE CAUSE Β0-THALASSEMIA
por: Ropero, P., et al.
Publicado: (2022)

PB2542: MOLECULAR SPECTRUM OF ALPHA THALASSEMIA MUTATIONS IN THE WESTERN PROVINCE OF SAUDI ARABIA AND RECOMMENDATION FOR PREMARITAL SCREENING
por: Attallah, Samy, et al.
Publicado: (2023)

PB2417: PRESENCE´S IMPACT OF NON-SPECIFIC ANTI-HLA ANTIBODIES ON THE DEVELOPMENT OF PRIMARY GRAFT FAILURE IN PATIENTS UNDERGOING PERIPHERAL BLOOD HAPLOIDENTICAL HSCT, EXPERIENCE AT A CENTER IN MEXICO.
por: Daniel Garza Escobar, Juan, et al.
Publicado: (2023)

PB2537: PREDICTORS OF BACTERIAL INFECTION AMONG TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS IN A TERTIARY GOVERNMENT HOSPITAL IN THE PHILIPPINES
por: Baylon, Angelica Kristine, et al.
Publicado: (2023)

PB2532: VARIABLE HEMATOLOGICAL AND CLINICAL PHENOTYPES IN DOUBLE HETEROZYGOTES OF ΒETA-THALASSEMIA AND TRIPLICATED ΑLPHA-GLOBIN GENES
por: Delaporta, Polyxeni, et al.
Publicado: (2023)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

Haploidentical CD3(+) TCR αβ/CD19(+)–depleted HSCT for MHC class II deficiency and persistent SARS-CoV-2 pneumonitis
por: Ramanathan, Subramaniam, et al.
Publicado: (2022)

PB2235: COMPLETE DELETION OF THE CACCC BOX OF THE HBB GENE PROMOTER: A NEW MECHANISM LEADING TO A SILENT PHENOTYPE OF BETA THALASSEMIA
por: Mondesert, E., et al.
Publicado: (2022)

PB2028: ACQUIRED Α-THALASSEMIA IN A PATIENT WITH HIGH-RISK MYELODYSPLASTIC SYNDROME AND BONE MARROW FIBROSIS: CASE REPORT AND LITERATURE REVIEW
por: Chissan, Sofia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rmkbng3j6tor469fdjtamfrq4v